The Career Development Award (CDA) is a research grant that provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. The cancer research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.
The Career Development Award (CDA) is a three-year cancer grant totaling $200,000, paid in three annual increments to the awardee’s institution.
The applicant must be a physician (MD, DO, or international equivalent) who is within the 1st to 3rd year of a full-time, primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission. Grant applications from candidates with existing career development awards (such as K23, K08, or any other type of career development award) will not be considered.
Applications for the 2014 CDA open on July 1, 2013. Read the 2014 Request for Proposals (RFP) for eligibility criteria and detailed instructions for submitting an application. Please note that this is a draft copy of the 2014 RFP. Applicants should visit the website on July 1, 2013 to download the final RFP.
The 2013 CDAs are supported by:
| Amgen | Lilly USA, LLC |
| The Breast Cancer Research Foundation | Millennium: The Takeda Oncology Company |
| Genentech BioOncology™ (4) | Roche Pharmaceuticals |
| GlaxoSmithKline Oncology |